Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Dose selection in phase I clinical trials in oncology

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Presentation
  • By: SCHELLENS, Jan (Netherlands Cancer Institute & University Utrecht, Clinical Pharmacology, Amsterdam, Netherlands)
  • Co-author(s): Jan HM Schellens: Clinical Pharmacology, Netherlands Cancer Institute & University Utrecht, Amsterdam, Netherlands
  • Abstract:

    Phase I studies in oncology are often carried out in patients with advanced cancer with the aim the select a safe dose and schedule for further testing in later phase II and III studies. Selection of the wrong dose and schedule can kill a good drug, which is a waist for patients and the pharmaceutical industry. Cabozantonib is a RET inhibitor

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses